Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosciences, demonstrate the ability of LX211 (LUVENIQ, voclosporin oral capsule) to significantly improve this chronic eye inflammation. Additionally, in patients who are discontinuing potentially toxic medications for uveitis, such as the corticosteroid prednisone, LX211 actively reduces the rate of inflammatory exacerbations by 50% at six months, compared to placebo. The study results also show a safety profile for LX211 at the 0.4 mg/kg bid dose that suggests the experimental drug would be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease, while also providing a means to greatly reduce the serious health risks associated with long-term corticosteroid use. LX211 is a novel and proprietary next-generation calcineurin inhibitor that Lux Biosciences is developing for ophthalmic uses.

Dr. James T. Rosenbaum, M.D., Professor of Ophthalmology, Medicine and Cell Biology and Vice-Chair of the Department of Ophthalmology of the Casey Eye Institute Oregon Health Sciences University (OHSU), represented the LUMINATE Investigator Network in presenting the Phase 3 LUMINATE program results for the first time at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The LUMINATE program, consisting of three randomized, double-masked, dose-ranging and placebo-controlled trials that enrolled a total of 558 patients at 56 sites in 7 countries (United States, Canada, United Kingdom, France, Germany, Austria and India), is the largest clinical program ever conducted in uveitis.

"Uveitis, a term used to classify a group of autoimmune diseases characterized by chronic inflammation of
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... WASHINGTON , Aug. 18, 2014   Sterne, ... law firm in Washington, DC , ... Inter Partes Review (IPR) with the U.S. ... Inc., a subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI). ... co-owned, or licensed by Myriad Genetics, Inc. These patents ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... 9, 2011 SPX Corporation (NYSE: SPW ... of B.W. Murdoch Ltd, a leading engineering company supplying ... company is based in Auckland, New Zealand. Terms of ... team has decades of experience in the New Zealand ...
... Md., March 9, 2011 The evidenced-based behavioral health ... Apple iPad; provides the clinician immediate clinical decision support ... is the first behavioral health site of its ... support for clinicians, and longitudinal monitoring for continuing care," ...
... 8, 2011 Leading events organiser UBM Live ... today announced details of the anticipated content and new developments ... leading International pharmaceutical event, being held from 18-20 April, 2011 ... line-up of events surrounding CPhI Japan includes P-MEC Japan, which ...
Cached Biology Technology:SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2M-3 Information, a Leader in Expert Behavioral Health Solutions, Launches M3Clinician.com 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 2UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 3UBM Announces Content for 10th Annual Japanese Pharma & Bio Events 4
(Date:8/19/2014)... concentrations of African dust transported to South America ... These research findings offer new insight on the ... African dust, including the climate change-induced human health ... African dust emissions in the coming decades., Researchers ... of Marine and Atmospheric Science and colleagues analyzed ...
(Date:8/19/2014)... forms, they have not been widely used due to ... the University of Surrey and Trinity College Dublin have ... graphene, to create a flexible sensor that is sensitive ... , Once treated, the rubber bands remain highly ... imparts an electromechanical response on movement the team ...
(Date:8/18/2014)... bacterial species in a person,s gut may protect against ... common cause of human bacterial intestinal inflammation, according research ... open-access journal of the American Society for Microbiology. The ... yield lasting changes to one,s gut bacteria composition. , ... the microbiota, or microorganisms in the gut, can protect ...
Breaking Biology News(10 mins):Study of African dust transport to South America reveals air quality impacts 2What's in your gut? Certain bacteria may influence susceptibility to infection 2
... Reportlinker.com announces that a new market research report ... US Biologics  Market ... exceed $100 billion by 2015 ... in 2015, experiencing continuing strong growth following a ...
... A new insight into global photosynthesis, the chemical process governing ... has been revealed in research that will assist scientists to ... published today in Nature , a team of US, ... of photosynthesis, the chemical process governing the way ocean and ...
... expert opinion of over 10,000 internationally renowned scientists and clinicians, ... looking at the research literature. A measure of how scientists ... rating system of articles, where named F1000 members score research ... these to generate a score for each journal that has ...
Cached Biology News:US Biologics Market 2US Biologics Market 3US Biologics Market 4US Biologics Market 5US Biologics Market 6US Biologics Market 7A new leaf turns in carbon science 2A new leaf turns in carbon science 3Faculty of 1000 introduces a unique opinion-based journal metric 2
... Early Drug Development with Imaging Mass Spectrometry ... compound localization data in early drug development ... spectrometry service maps unlabeled ions ... you can localize drugs and metabolites prior ...
... The AccuSpot automates LC micro-fractionation, ... With the AccuSpot system, LC eluent ... onto target plates, in trace amounts. ... target plates for MALDI-TOF-MS measurements. When ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
... knockdown of all human, mouse, and ... Genomewide, predesigned siRNAs for a ... , Ready-to-use, convenient matching solutions for ... Cost-effective RNAi and downstream analysis ...
Biology Products: